1.53
0.05 (3.38%)
| Previous Close | 1.48 |
| Open | 1.50 |
| Volume | 269,131 |
| Avg. Volume (3M) | 848,834 |
| Market Cap | 96,785,552 |
| Price / Sales | 0.690 |
| Price / Book | 1.29 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -36.23% |
| Operating Margin (TTM) | -323.11% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | 44.90% |
| Quarterly Earnings Growth (YOY) | 220.80% |
| Total Debt/Equity (MRQ) | 47.35% |
| Current Ratio (MRQ) | 3.28 |
| Operating Cash Flow (TTM) | -69.62 M |
| Levered Free Cash Flow (TTM) | -40.45 M |
| Return on Assets (TTM) | -26.29% |
| Return on Equity (TTM) | -60.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | MacroGenics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.88 |
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.01% |
| % Held by Institutions | 73.84% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 3.00 (Barclays, 96.08%) | Buy |
| Median | 2.50 (63.40%) | |
| Low | 2.00 (HC Wainwright & Co., 30.72%) | Hold |
| Average | 2.50 (63.40%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 1.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Nov 2025 | 2.00 (30.72%) | Hold | 1.58 |
| Barclays | 17 Sep 2025 | 3.00 (96.08%) | Buy | 1.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference |
| 12 Nov 2025 | Announcement | MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress |
| 06 Nov 2025 | Announcement | MacroGenics to Participate in the Stifel 2025 Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |